

Global Chiral Anticancer Intermediates Market Growth 2026-2032

<https://marketpublishers.com/r/G8079A4AF4CCEN.html>

Date: July 2026

Pages: 173

Price: US\$ 3,660.00 (Single User License)

ID: G8079A4AF4CCEN

Abstracts

The global Chiral Anticancer Intermediates market size is predicted to grow from US\$ 1235 million in 2025 to US\$ 2310 million in 2032; it is expected to grow at a CAGR of 9.8% from 2026 to 2032.

Chiral anticancer intermediates refer to structurally defined intermediates with well-controlled stereochemistry (typically >99% enantiomeric excess) that directly determine the pharmacologically active configuration of anticancer APIs; unlike general chiral intermediates, they are typically embedded in the core pharmacophore or target-binding stereochemical motifs rather than peripheral substituents, and their synthesis relies heavily on asymmetric catalysis (e.g., chiral ligands, biocatalysis) or resolution technologies, resulting in significantly higher process complexity and development risk; demand is tightly linked to oncology innovation pipelines (e.g., kinase inhibitors, PARP inhibitors, ADC payloads), leading to a characteristic profile of low volume, high value, and strong project-level coupling, which justifies treating this segment as a distinct, innovation-driven, high-barrier niche within the broader chiral intermediate market.

Corresponding to an implied demand volume of ~1,150 tons (derived from a blended ASP of ~USD 11,000/kg); kinase inhibitor-related intermediates account for ~58%, ADC-related (linker + payload) ~17%, PARP/DDR ~13%, and cytotoxic drugs ~12%; on the supply side, nominal capacity is estimated at ~2,800-3,200 tons (multi-purpose CDMO lines, nameplate basis), with utilization at ~35-40%, reflecting project-driven production dynamics; pricing shows strong stratification with core pharmacophore intermediates at ~USD 18,000/kg, side-chain intermediates at ~USD 6,500/kg, and ADC-related intermediates at ~USD 45,000/kg, resulting in a blended ASP of ~USD 11,000/kg and an industry-level gross margin of ~42%; downstream demand is concentrated in small molecule targeted therapies (~65%), ADCs (~20%), and cytotoxic chemotherapy

(~15%), while upstream relies on chiral catalysts (ligands/enzymes), high-purity solvents, and KSMs; the industry exhibits a global division of labor where Western players dominate high-potency and complex molecules, while China/India provide scale and cost efficiency; overall, the market is in the mid-growth stage, driven by increasing molecular complexity in oncology pipelines (notably ADCs and emerging modalities), with key uncertainties including biocatalysis substitution and API backward integration eroding the standalone intermediate market boundary.

LP Information, Inc. (LPI) ' newest research report, the "Chiral Anticancer Intermediates Industry Forecast" looks at past sales and reviews total world Chiral Anticancer Intermediates sales in 2025, providing a comprehensive analysis by region and market sector of projected Chiral Anticancer Intermediates sales for 2026 through 2032. With Chiral Anticancer Intermediates sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Chiral Anticancer Intermediates industry.

This Insight Report provides a comprehensive analysis of the global Chiral Anticancer Intermediates landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Chiral Anticancer Intermediates portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Chiral Anticancer Intermediates market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Chiral Anticancer Intermediates and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Chiral Anticancer Intermediates.

This report presents a comprehensive overview, market shares, and growth opportunities of Chiral Anticancer Intermediates market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Asymmetric Catalysis-derived

Biocatalysis-derived

Chiral Pool-derived

Resolution-based

Segmentation by Function:

Pharmacophore Core Intermediates

Side-chain Chiral Intermediates

Linker-related Chiral Units

Payload-related Intermediates

Segmentation by Application:

Small Molecule Targeted Therapy

Cytotoxic Chemotherapy

Antibody-Drug Conjugates (ADC)

Hormonal Therapy

Emerging Modalities-linked Small Molecules

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Lonza

WuXi AppTec

WuXi STA

Asymchem

Pharmaron

Porton Pharma

STA Pharmaceutical

Siegfried Holding

Evonik Health Care

Cambrex

Ajinomoto Bio-Pharma

Piramal Pharma Solutions

Almac Group

Carbogen Amcis

Hovione

Dishman Carbogen Amcis

Zhejiang Jiuzhou Pharma

Zhejiang Huahai Pharma

Jiangsu Hengrui Pharma

Ascent Scientific (API arm)

BASF Pharma Solutions

Johnson Matthey

Solvias

Codexis

Enamine

Jubilant Pharmova

Laurus Labs

Key Questions Addressed in this Report

What is the 10-year outlook for the global Chiral Anticancer Intermediates market?

What factors are driving Chiral Anticancer Intermediates market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Chiral Anticancer Intermediates market opportunities vary by end market size?

How does Chiral Anticancer Intermediates break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Chiral Anticancer Intermediates Annual Sales 2021-2032
 - 2.1.2 World Current & Future Analysis for Chiral Anticancer Intermediates by Geographic Region, 2021, 2025 & 2032
 - 2.1.3 World Current & Future Analysis for Chiral Anticancer Intermediates by Country/Region, 2021, 2025 & 2032
- 2.2 Chiral Anticancer Intermediates Segment by Type
 - 2.2.1 Asymmetric Catalysis-derived
 - 2.2.2 Biocatalysis-derived
 - 2.2.3 Chiral Pool-derived
 - 2.2.4 Resolution-based
 - 2.2.5 Chiral Anticancer Intermediates Sales by Type
 - 2.2.5.1 Global Chiral Anticancer Intermediates Sales Market Share by Type (2021-2026)
 - 2.2.5.2 Global Chiral Anticancer Intermediates Revenue and Market Share by Type (2021-2026)
 - 2.2.5.3 Global Chiral Anticancer Intermediates Sale Price by Type (2021-2026)
- 2.3 Chiral Anticancer Intermediates Segment by Function
 - 2.3.1 Pharmacophore Core Intermediates
 - 2.3.2 Side-chain Chiral Intermediates
 - 2.3.3 Linker-related Chiral Units
 - 2.3.4 Payload-related Intermediates
 - 2.3.5 Chiral Anticancer Intermediates Sales by Function
 - 2.3.5.1 Global Chiral Anticancer Intermediates Sales Market Share by Function

(2021-2026)

2.3.5.2 Global Chiral Anticancer Intermediates Revenue and Market Share by Function (2021-2026)

2.3.5.3 Global Chiral Anticancer Intermediates Sale Price by Function (2021-2026)

2.4 Chiral Anticancer Intermediates Segment by Application

2.4.1 Small Molecule Targeted Therapy

2.4.2 Cytotoxic Chemotherapy

2.4.3 Antibody-Drug Conjugates (ADC)

2.4.4 Hormonal Therapy

2.4.5 Emerging Modalities-linked Small Molecules

2.4.6 Chiral Anticancer Intermediates Sales by Application

2.4.6.1 Global Chiral Anticancer Intermediates Sale Market Share by Application (2021-2026)

2.4.6.2 Global Chiral Anticancer Intermediates Revenue and Market Share by Application (2021-2026)

2.4.6.3 Global Chiral Anticancer Intermediates Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Chiral Anticancer Intermediates Breakdown Data by Company

3.1.1 Global Chiral Anticancer Intermediates Annual Sales by Company (2021-2026)

3.1.2 Global Chiral Anticancer Intermediates Sales Market Share by Company (2021-2026)

3.2 Global Chiral Anticancer Intermediates Annual Revenue by Company (2021-2026)

3.2.1 Global Chiral Anticancer Intermediates Revenue by Company (2021-2026)

3.2.2 Global Chiral Anticancer Intermediates Revenue Market Share by Company (2021-2026)

3.3 Global Chiral Anticancer Intermediates Sale Price by Company

3.4 Key Manufacturers Chiral Anticancer Intermediates Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Chiral Anticancer Intermediates Product Location Distribution

3.4.2 Players Chiral Anticancer Intermediates Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR CHIRAL ANTICANCER INTERMEDIATES BY

GEOGRAPHIC REGION

4.1 World Historic Chiral Anticancer Intermediates Market Size by Geographic Region (2021-2026)

4.1.1 Global Chiral Anticancer Intermediates Annual Sales by Geographic Region (2021-2026)

4.1.2 Global Chiral Anticancer Intermediates Annual Revenue by Geographic Region (2021-2026)

4.2 World Historic Chiral Anticancer Intermediates Market Size by Country/Region (2021-2026)

4.2.1 Global Chiral Anticancer Intermediates Annual Sales by Country/Region (2021-2026)

4.2.2 Global Chiral Anticancer Intermediates Annual Revenue by Country/Region (2021-2026)

4.3 Americas Chiral Anticancer Intermediates Sales Growth

4.4 APAC Chiral Anticancer Intermediates Sales Growth

4.5 Europe Chiral Anticancer Intermediates Sales Growth

4.6 Middle East & Africa Chiral Anticancer Intermediates Sales Growth

5 AMERICAS

5.1 Americas Chiral Anticancer Intermediates Sales by Country

5.1.1 Americas Chiral Anticancer Intermediates Sales by Country (2021-2026)

5.1.2 Americas Chiral Anticancer Intermediates Revenue by Country (2021-2026)

5.2 Americas Chiral Anticancer Intermediates Sales by Type (2021-2026)

5.3 Americas Chiral Anticancer Intermediates Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Chiral Anticancer Intermediates Sales by Region

6.1.1 APAC Chiral Anticancer Intermediates Sales by Region (2021-2026)

6.1.2 APAC Chiral Anticancer Intermediates Revenue by Region (2021-2026)

6.2 APAC Chiral Anticancer Intermediates Sales by Type (2021-2026)

6.3 APAC Chiral Anticancer Intermediates Sales by Application (2021-2026)

6.4 China

- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

- 7.1 Europe Chiral Anticancer Intermediates by Country
 - 7.1.1 Europe Chiral Anticancer Intermediates Sales by Country (2021-2026)
 - 7.1.2 Europe Chiral Anticancer Intermediates Revenue by Country (2021-2026)
- 7.2 Europe Chiral Anticancer Intermediates Sales by Type (2021-2026)
- 7.3 Europe Chiral Anticancer Intermediates Sales by Application (2021-2026)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Chiral Anticancer Intermediates by Country
 - 8.1.1 Middle East & Africa Chiral Anticancer Intermediates Sales by Country (2021-2026)
 - 8.1.2 Middle East & Africa Chiral Anticancer Intermediates Revenue by Country (2021-2026)
- 8.2 Middle East & Africa Chiral Anticancer Intermediates Sales by Type (2021-2026)
- 8.3 Middle East & Africa Chiral Anticancer Intermediates Sales by Application (2021-2026)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Chiral Anticancer Intermediates

10.3 Manufacturing Process Analysis of Chiral Anticancer Intermediates

10.4 Industry Chain Structure of Chiral Anticancer Intermediates

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Chiral Anticancer Intermediates Distributors

11.3 Chiral Anticancer Intermediates Customer

12 WORLD FORECAST REVIEW FOR CHIRAL ANTICANCER INTERMEDIATES BY GEOGRAPHIC REGION

12.1 Global Chiral Anticancer Intermediates Market Size Forecast by Region

12.1.1 Global Chiral Anticancer Intermediates Forecast by Region (2027-2032)

12.1.2 Global Chiral Anticancer Intermediates Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global Chiral Anticancer Intermediates Forecast by Type (2027-2032)

12.7 Global Chiral Anticancer Intermediates Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 Lonza

13.1.1 Lonza Company Information

13.1.2 Lonza Chiral Anticancer Intermediates Product Portfolios and Specifications

13.1.3 Lonza Chiral Anticancer Intermediates Sales, Revenue, Price and Gross Margin (2021-2026)

- 13.1.4 Lonza Main Business Overview
- 13.1.5 Lonza Latest Developments
- 13.2 WuXi AppTec
 - 13.2.1 WuXi AppTec Company Information
 - 13.2.2 WuXi AppTec Chiral Anticancer Intermediates Product Portfolios and Specifications
 - 13.2.3 WuXi AppTec Chiral Anticancer Intermediates Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.2.4 WuXi AppTec Main Business Overview
 - 13.2.5 WuXi AppTec Latest Developments
- 13.3 WuXi STA
 - 13.3.1 WuXi STA Company Information
 - 13.3.2 WuXi STA Chiral Anticancer Intermediates Product Portfolios and Specifications
 - 13.3.3 WuXi STA Chiral Anticancer Intermediates Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.3.4 WuXi STA Main Business Overview
 - 13.3.5 WuXi STA Latest Developments
- 13.4 Asymchem
 - 13.4.1 Asymchem Company Information
 - 13.4.2 Asymchem Chiral Anticancer Intermediates Product Portfolios and Specifications
 - 13.4.3 Asymchem Chiral Anticancer Intermediates Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.4.4 Asymchem Main Business Overview
 - 13.4.5 Asymchem Latest Developments
- 13.5 Pharmaron
 - 13.5.1 Pharmaron Company Information
 - 13.5.2 Pharmaron Chiral Anticancer Intermediates Product Portfolios and Specifications
 - 13.5.3 Pharmaron Chiral Anticancer Intermediates Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.5.4 Pharmaron Main Business Overview
 - 13.5.5 Pharmaron Latest Developments
- 13.6 Porton Pharma
 - 13.6.1 Porton Pharma Company Information
 - 13.6.2 Porton Pharma Chiral Anticancer Intermediates Product Portfolios and Specifications
 - 13.6.3 Porton Pharma Chiral Anticancer Intermediates Sales, Revenue, Price and

Gross Margin (2021-2026)

13.6.4 Porton Pharma Main Business Overview

13.6.5 Porton Pharma Latest Developments

13.7 STA Pharmaceutical

13.7.1 STA Pharmaceutical Company Information

13.7.2 STA Pharmaceutical Chiral Anticancer Intermediates Product Portfolios and Specifications

13.7.3 STA Pharmaceutical Chiral Anticancer Intermediates Sales, Revenue, Price and Gross Margin (2021-2026)

13.7.4 STA Pharmaceutical Main Business Overview

13.7.5 STA Pharmaceutical Latest Developments

13.8 Siegfried Holding

13.8.1 Siegfried Holding Company Information

13.8.2 Siegfried Holding Chiral Anticancer Intermediates Product Portfolios and Specifications

13.8.3 Siegfried Holding Chiral Anticancer Intermediates Sales, Revenue, Price and Gross Margin (2021-2026)

13.8.4 Siegfried Holding Main Business Overview

13.8.5 Siegfried Holding Latest Developments

13.9 Evonik Health Care

13.9.1 Evonik Health Care Company Information

13.9.2 Evonik Health Care Chiral Anticancer Intermediates Product Portfolios and Specifications

13.9.3 Evonik Health Care Chiral Anticancer Intermediates Sales, Revenue, Price and Gross Margin (2021-2026)

13.9.4 Evonik Health Care Main Business Overview

13.9.5 Evonik Health Care Latest Developments

13.10 Cambrex

13.10.1 Cambrex Company Information

13.10.2 Cambrex Chiral Anticancer Intermediates Product Portfolios and Specifications

13.10.3 Cambrex Chiral Anticancer Intermediates Sales, Revenue, Price and Gross Margin (2021-2026)

13.10.4 Cambrex Main Business Overview

13.10.5 Cambrex Latest Developments

13.11 Ajinomoto Bio-Pharma

13.11.1 Ajinomoto Bio-Pharma Company Information

13.11.2 Ajinomoto Bio-Pharma Chiral Anticancer Intermediates Product Portfolios and Specifications

13.11.3 Ajinomoto Bio-Pharma Chiral Anticancer Intermediates Sales, Revenue, Price and Gross Margin (2021-2026)

13.11.4 Ajinomoto Bio-Pharma Main Business Overview

13.11.5 Ajinomoto Bio-Pharma Latest Developments

13.12 Piramal Pharma Solutions

13.12.1 Piramal Pharma Solutions Company Information

13.12.2 Piramal Pharma Solutions Chiral Anticancer Intermediates Product Portfolios and Specifications

13.12.3 Piramal Pharma Solutions Chiral Anticancer Intermediates Sales, Revenue, Price and Gross Margin (2021-2026)

13.12.4 Piramal Pharma Solutions Main Business Overview

13.12.5 Piramal Pharma Solutions Latest Developments

13.13 Almac Group

13.13.1 Almac Group Company Information

13.13.2 Almac Group Chiral Anticancer Intermediates Product Portfolios and Specifications

13.13.3 Almac Group Chiral Anticancer Intermediates Sales, Revenue, Price and Gross Margin (2021-2026)

13.13.4 Almac Group Main Business Overview

13.13.5 Almac Group Latest Developments

13.14 Carbogen Amcis

13.14.1 Carbogen Amcis Company Information

13.14.2 Carbogen Amcis Chiral Anticancer Intermediates Product Portfolios and Specifications

13.14.3 Carbogen Amcis Chiral Anticancer Intermediates Sales, Revenue, Price and Gross Margin (2021-2026)

13.14.4 Carbogen Amcis Main Business Overview

13.14.5 Carbogen Amcis Latest Developments

13.15 Hovione

13.15.1 Hovione Company Information

13.15.2 Hovione Chiral Anticancer Intermediates Product Portfolios and Specifications

13.15.3 Hovione Chiral Anticancer Intermediates Sales, Revenue, Price and Gross Margin (2021-2026)

13.15.4 Hovione Main Business Overview

13.15.5 Hovione Latest Developments

13.16 Dishman Carbogen Amcis

13.16.1 Dishman Carbogen Amcis Company Information

13.16.2 Dishman Carbogen Amcis Chiral Anticancer Intermediates Product Portfolios and Specifications

13.16.3 Dishman Carbogen Amcis Chiral Anticancer Intermediates Sales, Revenue, Price and Gross Margin (2021-2026)

13.16.4 Dishman Carbogen Amcis Main Business Overview

13.16.5 Dishman Carbogen Amcis Latest Developments

13.17 Zhejiang Jiuzhou Pharma

13.17.1 Zhejiang Jiuzhou Pharma Company Information

13.17.2 Zhejiang Jiuzhou Pharma Chiral Anticancer Intermediates Product Portfolios and Specifications

13.17.3 Zhejiang Jiuzhou Pharma Chiral Anticancer Intermediates Sales, Revenue, Price and Gross Margin (2021-2026)

13.17.4 Zhejiang Jiuzhou Pharma Main Business Overview

13.17.5 Zhejiang Jiuzhou Pharma Latest Developments

13.18 Zhejiang Huahai Pharma

13.18.1 Zhejiang Huahai Pharma Company Information

13.18.2 Zhejiang Huahai Pharma Chiral Anticancer Intermediates Product Portfolios and Specifications

13.18.3 Zhejiang Huahai Pharma Chiral Anticancer Intermediates Sales, Revenue, Price and Gross Margin (2021-2026)

13.18.4 Zhejiang Huahai Pharma Main Business Overview

13.18.5 Zhejiang Huahai Pharma Latest Developments

13.19 Jiangsu Hengrui Pharma

13.19.1 Jiangsu Hengrui Pharma Company Information

13.19.2 Jiangsu Hengrui Pharma Chiral Anticancer Intermediates Product Portfolios and Specifications

13.19.3 Jiangsu Hengrui Pharma Chiral Anticancer Intermediates Sales, Revenue, Price and Gross Margin (2021-2026)

13.19.4 Jiangsu Hengrui Pharma Main Business Overview

13.19.5 Jiangsu Hengrui Pharma Latest Developments

13.20 Ascent Scientific (API arm)

13.20.1 Ascent Scientific (API arm) Company Information

13.20.2 Ascent Scientific (API arm) Chiral Anticancer Intermediates Product Portfolios and Specifications

13.20.3 Ascent Scientific (API arm) Chiral Anticancer Intermediates Sales, Revenue, Price and Gross Margin (2021-2026)

13.20.4 Ascent Scientific (API arm) Main Business Overview

13.20.5 Ascent Scientific (API arm) Latest Developments

13.21 BASF Pharma Solutions

13.21.1 BASF Pharma Solutions Company Information

13.21.2 BASF Pharma Solutions Chiral Anticancer Intermediates Product Portfolios

and Specifications

13.21.3 BASF Pharma Solutions Chiral Anticancer Intermediates Sales, Revenue, Price and Gross Margin (2021-2026)

13.21.4 BASF Pharma Solutions Main Business Overview

13.21.5 BASF Pharma Solutions Latest Developments

13.22 Johnson Matthey

13.22.1 Johnson Matthey Company Information

13.22.2 Johnson Matthey Chiral Anticancer Intermediates Product Portfolios and Specifications

13.22.3 Johnson Matthey Chiral Anticancer Intermediates Sales, Revenue, Price and Gross Margin (2021-2026)

13.22.4 Johnson Matthey Main Business Overview

13.22.5 Johnson Matthey Latest Developments

13.23 Solvias

13.23.1 Solvias Company Information

13.23.2 Solvias Chiral Anticancer Intermediates Product Portfolios and Specifications

13.23.3 Solvias Chiral Anticancer Intermediates Sales, Revenue, Price and Gross Margin (2021-2026)

13.23.4 Solvias Main Business Overview

13.23.5 Solvias Latest Developments

13.24 Codexis

13.24.1 Codexis Company Information

13.24.2 Codexis Chiral Anticancer Intermediates Product Portfolios and Specifications

13.24.3 Codexis Chiral Anticancer Intermediates Sales, Revenue, Price and Gross Margin (2021-2026)

13.24.4 Codexis Main Business Overview

13.24.5 Codexis Latest Developments

13.25 Enamine

13.25.1 Enamine Company Information

13.25.2 Enamine Chiral Anticancer Intermediates Product Portfolios and Specifications

13.25.3 Enamine Chiral Anticancer Intermediates Sales, Revenue, Price and Gross Margin (2021-2026)

13.25.4 Enamine Main Business Overview

13.25.5 Enamine Latest Developments

13.26 Jubilant Pharmova

13.26.1 Jubilant Pharmova Company Information

13.26.2 Jubilant Pharmova Chiral Anticancer Intermediates Product Portfolios and Specifications

13.26.3 Jubilant Pharmova Chiral Anticancer Intermediates Sales, Revenue, Price and

Gross Margin (2021-2026)

13.26.4 Jubilant Pharmova Main Business Overview

13.26.5 Jubilant Pharmova Latest Developments

13.27 Laurus Labs

13.27.1 Laurus Labs Company Information

13.27.2 Laurus Labs Chiral Anticancer Intermediates Product Portfolios and Specifications

13.27.3 Laurus Labs Chiral Anticancer Intermediates Sales, Revenue, Price and Gross Margin (2021-2026)

13.27.4 Laurus Labs Main Business Overview

13.27.5 Laurus Labs Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Chiral Anticancer Intermediates Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. Chiral Anticancer Intermediates Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Asymmetric Catalysis-derived

Table 4. Major Players of Biocatalysis-derived

Table 5. Major Players of Chiral Pool-derived

Table 6. Major Players of Resolution-based

Table 7. Global Chiral Anticancer Intermediates Sales by Type (2021-2026) & (Tons)

Table 8. Global Chiral Anticancer Intermediates Sales Market Share by Type (2021-2026)

Table 9. Global Chiral Anticancer Intermediates Revenue by Type (2021-2026) & (\$ million)

Table 10. Global Chiral Anticancer Intermediates Revenue Market Share by Type (2021-2026)

Table 11. Global Chiral Anticancer Intermediates Sale Price by Type (2021-2026) & (US\$/Ton)

Table 12. Major Players of Pharmacophore Core Intermediates

Table 13. Major Players of Side-chain Chiral Intermediates

Table 14. Major Players of Linker-related Chiral Units

Table 15. Major Players of Payload-related Intermediates

Table 16. Global Chiral Anticancer Intermediates Sales by Function (2021-2026) & (Tons)

Table 17. Global Chiral Anticancer Intermediates Sales Market Share by Function (2021-2026)

Table 18. Global Chiral Anticancer Intermediates Revenue by Function (2021-2026) & (\$ million)

Table 19. Global Chiral Anticancer Intermediates Revenue Market Share by Function (2021-2026)

Table 20. Global Chiral Anticancer Intermediates Sale Price by Function (2021-2026) & (US\$/Ton)

Table 21. Global Chiral Anticancer Intermediates Sale by Application (2021-2026) & (Tons)

Table 22. Global Chiral Anticancer Intermediates Sale Market Share by Application (2021-2026)

Table 23. Global Chiral Anticancer Intermediates Revenue by Application (2021-2026) & (\$ million)

Table 24. Global Chiral Anticancer Intermediates Revenue Market Share by Application (2021-2026)

Table 25. Global Chiral Anticancer Intermediates Sale Price by Application (2021-2026) & (US\$/Ton)

Table 26. Global Chiral Anticancer Intermediates Sales by Company (2021-2026) & (Tons)

Table 27. Global Chiral Anticancer Intermediates Sales Market Share by Company (2021-2026)

Table 28. Global Chiral Anticancer Intermediates Revenue by Company (2021-2026) & (\$ millions)

Table 29. Global Chiral Anticancer Intermediates Revenue Market Share by Company (2021-2026)

Table 30. Global Chiral Anticancer Intermediates Sale Price by Company (2021-2026) & (US\$/Ton)

Table 31. Key Manufacturers Chiral Anticancer Intermediates Producing Area Distribution and Sales Area

Table 32. Players Chiral Anticancer Intermediates Products Offered

Table 33. Chiral Anticancer Intermediates Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 34. New Products and Potential Entrants

Table 35. Market M&A Activity & Strategy

Table 36. Global Chiral Anticancer Intermediates Sales by Geographic Region (2021-2026) & (Tons)

Table 37. Global Chiral Anticancer Intermediates Sales Market Share Geographic Region (2021-2026)

Table 38. Global Chiral Anticancer Intermediates Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 39. Global Chiral Anticancer Intermediates Revenue Market Share by Geographic Region (2021-2026)

Table 40. Global Chiral Anticancer Intermediates Sales by Country/Region (2021-2026) & (Tons)

Table 41. Global Chiral Anticancer Intermediates Sales Market Share by Country/Region (2021-2026)

Table 42. Global Chiral Anticancer Intermediates Revenue by Country/Region (2021-2026) & (\$ millions)

Table 43. Global Chiral Anticancer Intermediates Revenue Market Share by Country/Region (2021-2026)

Table 44. Americas Chiral Anticancer Intermediates Sales by Country (2021-2026) & (Tons)

Table 45. Americas Chiral Anticancer Intermediates Sales Market Share by Country (2021-2026)

Table 46. Americas Chiral Anticancer Intermediates Revenue by Country (2021-2026) & (\$ millions)

Table 47. Americas Chiral Anticancer Intermediates Sales by Type (2021-2026) & (Tons)

Table 48. Americas Chiral Anticancer Intermediates Sales by Application (2021-2026) & (Tons)

Table 49. APAC Chiral Anticancer Intermediates Sales by Region (2021-2026) & (Tons)

Table 50. APAC Chiral Anticancer Intermediates Sales Market Share by Region (2021-2026)

Table 51. APAC Chiral Anticancer Intermediates Revenue by Region (2021-2026) & (\$ millions)

Table 52. APAC Chiral Anticancer Intermediates Sales by Type (2021-2026) & (Tons)

Table 53. APAC Chiral Anticancer Intermediates Sales by Application (2021-2026) & (Tons)

Table 54. Europe Chiral Anticancer Intermediates Sales by Country (2021-2026) & (Tons)

Table 55. Europe Chiral Anticancer Intermediates Revenue by Country (2021-2026) & (\$ millions)

Table 56. Europe Chiral Anticancer Intermediates Sales by Type (2021-2026) & (Tons)

Table 57. Europe Chiral Anticancer Intermediates Sales by Application (2021-2026) & (Tons)

Table 58. Middle East & Africa Chiral Anticancer Intermediates Sales by Country (2021-2026) & (Tons)

Table 59. Middle East & Africa Chiral Anticancer Intermediates Revenue Market Share by Country (2021-2026)

Table 60. Middle East & Africa Chiral Anticancer Intermediates Sales by Type (2021-2026) & (Tons)

Table 61. Middle East & Africa Chiral Anticancer Intermediates Sales by Application (2021-2026) & (Tons)

Table 62. Key Market Drivers & Growth Opportunities of Chiral Anticancer Intermediates

Table 63. Key Market Challenges & Risks of Chiral Anticancer Intermediates

Table 64. Key Industry Trends of Chiral Anticancer Intermediates

Table 65. Chiral Anticancer Intermediates Raw Material

Table 66. Key Suppliers of Raw Materials

Table 67. Chiral Anticancer Intermediates Distributors List

Table 68. Chiral Anticancer Intermediates Customer List
Table 69. Global Chiral Anticancer Intermediates Sales Forecast by Region (2027-2032) & (Tons)
Table 70. Global Chiral Anticancer Intermediates Revenue Forecast by Region (2027-2032) & (\$ millions)
Table 71. Americas Chiral Anticancer Intermediates Sales Forecast by Country (2027-2032) & (Tons)
Table 72. Americas Chiral Anticancer Intermediates Annual Revenue Forecast by Country (2027-2032) & (\$ millions)
Table 73. APAC Chiral Anticancer Intermediates Sales Forecast by Region (2027-2032) & (Tons)
Table 74. APAC Chiral Anticancer Intermediates Annual Revenue Forecast by Region (2027-2032) & (\$ millions)
Table 75. Europe Chiral Anticancer Intermediates Sales Forecast by Country (2027-2032) & (Tons)
Table 76. Europe Chiral Anticancer Intermediates Revenue Forecast by Country (2027-2032) & (\$ millions)
Table 77. Middle East & Africa Chiral Anticancer Intermediates Sales Forecast by Country (2027-2032) & (Tons)
Table 78. Middle East & Africa Chiral Anticancer Intermediates Revenue Forecast by Country (2027-2032) & (\$ millions)
Table 79. Global Chiral Anticancer Intermediates Sales Forecast by Type (2027-2032) & (Tons)
Table 80. Global Chiral Anticancer Intermediates Revenue Forecast by Type (2027-2032) & (\$ millions)
Table 81. Global Chiral Anticancer Intermediates Sales Forecast by Application (2027-2032) & (Tons)
Table 82. Global Chiral Anticancer Intermediates Revenue Forecast by Application (2027-2032) & (\$ millions)
Table 83. Lonza Basic Information, Chiral Anticancer Intermediates Manufacturing Base, Sales Area and Its Competitors
Table 84. Lonza Chiral Anticancer Intermediates Product Portfolios and Specifications
Table 85. Lonza Chiral Anticancer Intermediates Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)
Table 86. Lonza Main Business
Table 87. Lonza Latest Developments
Table 88. WuXi AppTec Basic Information, Chiral Anticancer Intermediates Manufacturing Base, Sales Area and Its Competitors
Table 89. WuXi AppTec Chiral Anticancer Intermediates Product Portfolios and

Specifications

Table 90. WuXi AppTec Chiral Anticancer Intermediates Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 91. WuXi AppTec Main Business

Table 92. WuXi AppTec Latest Developments

Table 93. WuXi STA Basic Information, Chiral Anticancer Intermediates Manufacturing Base, Sales Area and Its Competitors

Table 94. WuXi STA Chiral Anticancer Intermediates Product Portfolios and Specifications

Table 95. WuXi STA Chiral Anticancer Intermediates Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 96. WuXi STA Main Business

Table 97. WuXi STA Latest Developments

Table 98. Asymchem Basic Information, Chiral Anticancer Intermediates Manufacturing Base, Sales Area and Its Competitors

Table 99. Asymchem Chiral Anticancer Intermediates Product Portfolios and Specifications

Table 100. Asymchem Chiral Anticancer Intermediates Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 101. Asymchem Main Business

Table 102. Asymchem Latest Developments

Table 103. Pharmaron Basic Information, Chiral Anticancer Intermediates Manufacturing Base, Sales Area and Its Competitors

Table 104. Pharmaron Chiral Anticancer Intermediates Product Portfolios and Specifications

Table 105. Pharmaron Chiral Anticancer Intermediates Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 106. Pharmaron Main Business

Table 107. Pharmaron Latest Developments

Table 108. Porton Pharma Basic Information, Chiral Anticancer Intermediates Manufacturing Base, Sales Area and Its Competitors

Table 109. Porton Pharma Chiral Anticancer Intermediates Product Portfolios and Specifications

Table 110. Porton Pharma Chiral Anticancer Intermediates Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 111. Porton Pharma Main Business

Table 112. Porton Pharma Latest Developments

Table 113. STA Pharmaceutical Basic Information, Chiral Anticancer Intermediates Manufacturing Base, Sales Area and Its Competitors

Table 114. STA Pharmaceutical Chiral Anticancer Intermediates Product Portfolios and Specifications
Table 115. STA Pharmaceutical Chiral Anticancer Intermediates Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)
Table 116. STA Pharmaceutical Main Business
Table 117. STA Pharmaceutical Latest Developments
Table 118. Siegfried Holding Basic Information, Chiral Anticancer Intermediates Manufacturing Base, Sales Area and Its Competitors
Table 119. Siegfried Holding Chiral Anticancer Intermediates Product Portfolios and Specifications
Table 120. Siegfried Holding Chiral Anticancer Intermediates Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)
Table 121. Siegfried Holding Main Business
Table 122. Siegfried Holding Latest Developments
Table 123. Evonik Health Care Basic Information, Chiral Anticancer Intermediates Manufacturing Base, Sales Area and Its Competitors
Table 124. Evonik Health Care Chiral Anticancer Intermediates Product Portfolios and Specifications
Table 125. Evonik Health Care Chiral Anticancer Intermediates Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)
Table 126. Evonik Health Care Main Business
Table 127. Evonik Health Care Latest Developments
Table 128. Cambrex Basic Information, Chiral Anticancer Intermediates Manufacturing Base, Sales Area and Its Competitors
Table 129. Cambrex Chiral Anticancer Intermediates Product Portfolios and Specifications
Table 130. Cambrex Chiral Anticancer Intermediates Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)
Table 131. Cambrex Main Business
Table 132. Cambrex Latest Developments
Table 133. Ajinomoto Bio-Pharma Basic Information, Chiral Anticancer Intermediates Manufacturing Base, Sales Area and Its Competitors
Table 134. Ajinomoto Bio-Pharma Chiral Anticancer Intermediates Product Portfolios and Specifications
Table 135. Ajinomoto Bio-Pharma Chiral Anticancer Intermediates Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)
Table 136. Ajinomoto Bio-Pharma Main Business
Table 137. Ajinomoto Bio-Pharma Latest Developments
Table 138. Piramal Pharma Solutions Basic Information, Chiral Anticancer

Intermediates Manufacturing Base, Sales Area and Its Competitors

Table 139. Piramal Pharma Solutions Chiral Anticancer Intermediates Product Portfolios and Specifications

Table 140. Piramal Pharma Solutions Chiral Anticancer Intermediates Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 141. Piramal Pharma Solutions Main Business

Table 142. Piramal Pharma Solutions Latest Developments

Table 143. Almac Group Basic Information, Chiral Anticancer Intermediates Manufacturing Base, Sales Area and Its Competitors

Table 144. Almac Group Chiral Anticancer Intermediates Product Portfolios and Specifications

Table 145. Almac Group Chiral Anticancer Intermediates Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 146. Almac Group Main Business

Table 147. Almac Group Latest Developments

Table 148. Carbogen Amcis Basic Information, Chiral Anticancer Intermediates Manufacturing Base, Sales Area and Its Competitors

Table 149. Carbogen Amcis Chiral Anticancer Intermediates Product Portfolios and Specifications

Table 150. Carbogen Amcis Chiral Anticancer Intermediates Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 151. Carbogen Amcis Main Business

Table 152. Carbogen Amcis Latest Developments

Table 153. Hovione Basic Information, Chiral Anticancer Intermediates Manufacturing Base, Sales Area and Its Competitors

Table 154. Hovione Chiral Anticancer Intermediates Product Portfolios and Specifications

Table 155. Hovione Chiral Anticancer Intermediates Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 156. Hovione Main Business

Table 157. Hovione Latest Developments

Table 158. Dishman Carbogen Amcis Basic Information, Chiral Anticancer Intermediates Manufacturing Base, Sales Area and Its Competitors

Table 159. Dishman Carbogen Amcis Chiral Anticancer Intermediates Product Portfolios and Specifications

Table 160. Dishman Carbogen Amcis Chiral Anticancer Intermediates Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 161. Dishman Carbogen Amcis Main Business

Table 162. Dishman Carbogen Amcis Latest Developments

Table 163. Zhejiang Jiuzhou Pharma Basic Information, Chiral Anticancer Intermediates Manufacturing Base, Sales Area and Its Competitors

Table 164. Zhejiang Jiuzhou Pharma Chiral Anticancer Intermediates Product Portfolios and Specifications

Table 165. Zhejiang Jiuzhou Pharma Chiral Anticancer Intermediates Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 166. Zhejiang Jiuzhou Pharma Main Business

Table 167. Zhejiang Jiuzhou Pharma Latest Developments

Table 168. Zhejiang Huahai Pharma Basic Information, Chiral Anticancer Intermediates Manufacturing Base, Sales Area and Its Competitors

Table 169. Zhejiang Huahai Pharma Chiral Anticancer Intermediates Product Portfolios and Specifications

Table 170. Zhejiang Huahai Pharma Chiral Anticancer Intermediates Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 171. Zhejiang Huahai Pharma Main Business

Table 172. Zhejiang Huahai Pharma Latest Developments

Table 173. Jiangsu Hengrui Pharma Basic Information, Chiral Anticancer Intermediates Manufacturing Base, Sales Area and Its Competitors

Table 174. Jiangsu Hengrui Pharma Chiral Anticancer Intermediates Product Portfolios and Specifications

Table 175. Jiangsu Hengrui Pharma Chiral Anticancer Intermediates Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 176. Jiangsu Hengrui Pharma Main Business

Table 177. Jiangsu Hengrui Pharma Latest Developments

Table 178. Ascent Scientific (API arm) Basic Information, Chiral Anticancer Intermediates Manufacturing Base, Sales Area and Its Competitors

Table 179. Ascent Scientific (API arm) Chiral Anticancer Intermediates Product Portfolios and Specifications

Table 180. Ascent Scientific (API arm) Chiral Anticancer Intermediates Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 181. Ascent Scientific (API arm) Main Business

Table 182. Ascent Scientific (API arm) Latest Developments

Table 183. BASF Pharma Solutions Basic Information, Chiral Anticancer Intermediates Manufacturing Base, Sales Area and Its Competitors

Table 184. BASF Pharma Solutions Chiral Anticancer Intermediates Product Portfolios and Specifications

Table 185. BASF Pharma Solutions Chiral Anticancer Intermediates Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 186. BASF Pharma Solutions Main Business

Table 187. BASF Pharma Solutions Latest Developments

Table 188. Johnson Matthey Basic Information, Chiral Anticancer Intermediates Manufacturing Base, Sales Area and Its Competitors

Table 189. Johnson Matthey Chiral Anticancer Intermediates Product Portfolios and Specifications

Table 190. Johnson Matthey Chiral Anticancer Intermediates Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 191. Johnson Matthey Main Business

Table 192. Johnson Matthey Latest Developments

Table 193. Solvias Basic Information, Chiral Anticancer Intermediates Manufacturing Base, Sales Area and Its Competitors

Table 194. Solvias Chiral Anticancer Intermediates Product Portfolios and Specifications

Table 195. Solvias Chiral Anticancer Intermediates Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 196. Solvias Main Business

Table 197. Solvias Latest Developments

Table 198. Codexis Basic Information, Chiral Anticancer Intermediates Manufacturing Base, Sales Area and Its Competitors

Table 199. Codexis Chiral Anticancer Intermediates Product Portfolios and Specifications

Table 200. Codexis Chiral Anticancer Intermediates Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 201. Codexis Main Business

Table 202. Codexis Latest Developments

Table 203. Enamine Basic Information, Chiral Anticancer Intermediates Manufacturing Base, Sales Area and Its Competitors

Table 204. Enamine Chiral Anticancer Intermediates Product Portfolios and Specifications

Table 205. Enamine Chiral Anticancer Intermediates Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 206. Enamine Main Business

Table 207. Enamine Latest Developments

Table 208. Jubilant Pharmova Basic Information, Chiral Anticancer Intermediates Manufacturing Base, Sales Area and Its Competitors

Table 209. Jubilant Pharmova Chiral Anticancer Intermediates Product Portfolios and Specifications

Table 210. Jubilant Pharmova Chiral Anticancer Intermediates Sales (Tons), Revenue (\$ Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 211. Jubilant Pharmova Main Business

Table 212. Jubilant Pharmova Latest Developments

Table 213. Laurus Labs Basic Information, Chiral Anticancer Intermediates
Manufacturing Base, Sales Area and Its Competitors

Table 214. Laurus Labs Chiral Anticancer Intermediates Product Portfolios and
Specifications

Table 215. Laurus Labs Chiral Anticancer Intermediates Sales (Tons), Revenue (\$
Million), Price (US\$/Ton) and Gross Margin (2021-2026)

Table 216. Laurus Labs Main Business

Table 217. Laurus Labs Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Chiral Anticancer Intermediates
- Figure 2. Chiral Anticancer Intermediates Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Chiral Anticancer Intermediates Sales Growth Rate 2021-2032 (Tons)
- Figure 7. Global Chiral Anticancer Intermediates Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. Chiral Anticancer Intermediates Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. Chiral Anticancer Intermediates Sales Market Share by Country/Region (2025)
- Figure 10. Chiral Anticancer Intermediates Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of Asymmetric Catalysis-derived
- Figure 12. Product Picture of Biocatalysis-derived
- Figure 13. Product Picture of Chiral Pool-derived
- Figure 14. Product Picture of Resolution-based
- Figure 15. Global Chiral Anticancer Intermediates Sales Market Share by Type in 2026
- Figure 16. Global Chiral Anticancer Intermediates Revenue Market Share by Type (2021-2026)
- Figure 17. Product Picture of Pharmacophore Core Intermediates
- Figure 18. Product Picture of Side-chain Chiral Intermediates
- Figure 19. Product Picture of Linker-related Chiral Units
- Figure 20. Product Picture of Payload-related Intermediates
- Figure 21. Global Chiral Anticancer Intermediates Sales Market Share by Function in 2026
- Figure 22. Global Chiral Anticancer Intermediates Revenue Market Share by Function (2021-2026)
- Figure 23. Chiral Anticancer Intermediates Consumed in Small Molecule Targeted Therapy
- Figure 24. Global Chiral Anticancer Intermediates Market: Small Molecule Targeted Therapy (2021-2026) & (Tons)
- Figure 25. Chiral Anticancer Intermediates Consumed in Cytotoxic Chemotherapy
- Figure 26. Global Chiral Anticancer Intermediates Market: Cytotoxic Chemotherapy (2021-2026) & (Tons)

Figure 27. Chiral Anticancer Intermediates Consumed in Antibody-Drug Conjugates (ADC)

Figure 28. Global Chiral Anticancer Intermediates Market: Antibody-Drug Conjugates (ADC) (2021-2026) & (Tons)

Figure 29. Chiral Anticancer Intermediates Consumed in Hormonal Therapy

Figure 30. Global Chiral Anticancer Intermediates Market: Hormonal Therapy (2021-2026) & (Tons)

Figure 31. Chiral Anticancer Intermediates Consumed in Emerging Modalities-linked Small Molecules

Figure 32. Global Chiral Anticancer Intermediates Market: Emerging Modalities-linked Small Molecules (2021-2026) & (Tons)

Figure 33. Global Chiral Anticancer Intermediates Sale Market Share by Application (2025)

Figure 34. Global Chiral Anticancer Intermediates Revenue Market Share by Application in 2025

Figure 35. Chiral Anticancer Intermediates Sales by Company in 2025 (Tons)

Figure 36. Global Chiral Anticancer Intermediates Sales Market Share by Company in 2025

Figure 37. Chiral Anticancer Intermediates Revenue by Company in 2025 (\$ millions)

Figure 38. Global Chiral Anticancer Intermediates Revenue Market Share by Company in 2025

Figure 39. Global Chiral Anticancer Intermediates Sales Market Share by Geographic Region (2021-2026)

Figure 40. Global Chiral Anticancer Intermediates Revenue Market Share by Geographic Region in 2025

Figure 41. Americas Chiral Anticancer Intermediates Sales 2021-2026 (Tons)

Figure 42. Americas Chiral Anticancer Intermediates Revenue 2021-2026 (\$ millions)

Figure 43. APAC Chiral Anticancer Intermediates Sales 2021-2026 (Tons)

Figure 44. APAC Chiral Anticancer Intermediates Revenue 2021-2026 (\$ millions)

Figure 45. Europe Chiral Anticancer Intermediates Sales 2021-2026 (Tons)

Figure 46. Europe Chiral Anticancer Intermediates Revenue 2021-2026 (\$ millions)

Figure 47. Middle East & Africa Chiral Anticancer Intermediates Sales 2021-2026 (Tons)

Figure 48. Middle East & Africa Chiral Anticancer Intermediates Revenue 2021-2026 (\$ millions)

Figure 49. Americas Chiral Anticancer Intermediates Sales Market Share by Country in 2025

Figure 50. Americas Chiral Anticancer Intermediates Revenue Market Share by Country (2021-2026)

Figure 51. Americas Chiral Anticancer Intermediates Sales Market Share by Type (2021-2026)

Figure 52. Americas Chiral Anticancer Intermediates Sales Market Share by Application (2021-2026)

Figure 53. United States Chiral Anticancer Intermediates Revenue Growth 2021-2026 (\$ millions)

Figure 54. Canada Chiral Anticancer Intermediates Revenue Growth 2021-2026 (\$ millions)

Figure 55. Mexico Chiral Anticancer Intermediates Revenue Growth 2021-2026 (\$ millions)

Figure 56. Brazil Chiral Anticancer Intermediates Revenue Growth 2021-2026 (\$ millions)

Figure 57. APAC Chiral Anticancer Intermediates Sales Market Share by Region in 2025

Figure 58. APAC Chiral Anticancer Intermediates Revenue Market Share by Region (2021-2026)

Figure 59. APAC Chiral Anticancer Intermediates Sales Market Share by Type (2021-2026)

Figure 60. APAC Chiral Anticancer Intermediates Sales Market Share by Application (2021-2026)

Figure 61. China Chiral Anticancer Intermediates Revenue Growth 2021-2026 (\$ millions)

Figure 62. Japan Chiral Anticancer Intermediates Revenue Growth 2021-2026 (\$ millions)

Figure 63. South Korea Chiral Anticancer Intermediates Revenue Growth 2021-2026 (\$ millions)

Figure 64. Southeast Asia Chiral Anticancer Intermediates Revenue Growth 2021-2026 (\$ millions)

Figure 65. India Chiral Anticancer Intermediates Revenue Growth 2021-2026 (\$ millions)

Figure 66. Australia Chiral Anticancer Intermediates Revenue Growth 2021-2026 (\$ millions)

Figure 67. China Taiwan Chiral Anticancer Intermediates Revenue Growth 2021-2026 (\$ millions)

Figure 68. Europe Chiral Anticancer Intermediates Sales Market Share by Country in 2025

Figure 69. Europe Chiral Anticancer Intermediates Revenue Market Share by Country (2021-2026)

Figure 70. Europe Chiral Anticancer Intermediates Sales Market Share by Type

(2021-2026)

Figure 71. Europe Chiral Anticancer Intermediates Sales Market Share by Application (2021-2026)

Figure 72. Germany Chiral Anticancer Intermediates Revenue Growth 2021-2026 (\$ millions)

Figure 73. France Chiral Anticancer Intermediates Revenue Growth 2021-2026 (\$ millions)

Figure 74. UK Chiral Anticancer Intermediates Revenue Growth 2021-2026 (\$ millions)

Figure 75. Italy Chiral Anticancer Intermediates Revenue Growth 2021-2026 (\$ millions)

Figure 76. Russia Chiral Anticancer Intermediates Revenue Growth 2021-2026 (\$ millions)

Figure 77. Middle East & Africa Chiral Anticancer Intermediates Sales Market Share by Country (2021-2026)

Figure 78. Middle East & Africa Chiral Anticancer Intermediates Sales Market Share by Type (2021-2026)

Figure 79. Middle East & Africa Chiral Anticancer Intermediates Sales Market Share by Application (2021-2026)

Figure 80. Egypt Chiral Anticancer Intermediates Revenue Growth 2021-2026 (\$ millions)

Figure 81. South Africa Chiral Anticancer Intermediates Revenue Growth 2021-2026 (\$ millions)

Figure 82. Israel Chiral Anticancer Intermediates Revenue Growth 2021-2026 (\$ millions)

Figure 83. Turkey Chiral Anticancer Intermediates Revenue Growth 2021-2026 (\$ millions)

Figure 84. GCC Countries Chiral Anticancer Intermediates Revenue Growth 2021-2026 (\$ millions)

Figure 85. Manufacturing Cost Structure Analysis of Chiral Anticancer Intermediates in 2026

Figure 86. Manufacturing Process Analysis of Chiral Anticancer Intermediates

Figure 87. Industry Chain Structure of Chiral Anticancer Intermediates

Figure 88. Channels of Distribution

Figure 89. Global Chiral Anticancer Intermediates Sales Market Forecast by Region (2027-2032)

Figure 90. Global Chiral Anticancer Intermediates Revenue Market Share Forecast by Region (2027-2032)

Figure 91. Global Chiral Anticancer Intermediates Sales Market Share Forecast by Type (2027-2032)

Figure 92. Global Chiral Anticancer Intermediates Revenue Market Share Forecast by

Type (2027-2032)

Figure 93. Global Chiral Anticancer Intermediates Sales Market Share Forecast by Application (2027-2032)

Figure 94. Global Chiral Anticancer Intermediates Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Chiral Anticancer Intermediates Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/G8079A4AF4CCEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G8079A4AF4CCEN.html>